Drugs / repository corticotropin injection
repository corticotropin injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02919761 | Nov 2016 → Oct 2018 | rheumatoid arthritis | Mallinckrodt | Completed | Mixed |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Mallinckrodt | Results Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research gcs-web.com ↗
Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Mallinckrodt | Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research gcs-web.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | repository corticotropin injection | “Repository corticotropin injection (RCI, Acthar® Gel) is approved as adjunctive therapy for short-term administration in patients with continued RA disease activity.” PMID 32497440 ↗ Jun 2020 |
| Known as | Acthar Gel | “Repository corticotropin injection (RCI, Acthar® Gel) is approved as adjunctive therapy for short-term administration in patients with continued RA disease activity.” PMID 32497440 ↗ Jun 2020 |
| Known as | RCI | “Repository corticotropin injection (RCI, Acthar® Gel) is approved as adjunctive therapy for short-term administration in patients with continued RA disease activity.” PMID 32497440 ↗ Jun 2020 |
| Route | Subcutaneous | “80 Units Acthar Gel per 1 mL for subcutaneous injection” NCT02919761 ↗ |